View Older Stories View More Recent Stories

Apr 25, 2019 07:30AM Viking Therapeutics to Report Financial Results for First Quarter 2019 on May 2, 2019
Apr 11, 2019 07:03AM Viking Therapeutics (VKTX) Presents New Data from Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol at EASL
Apr 11, 2019 07:02AM Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
Apr 4, 2019 07:32AM Viking (VKTX) to Present New Data from Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol
Apr 4, 2019 07:30AM Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
Mar 28, 2019 07:30AM Viking Therapeutics to Participate in Upcoming Investor Conferences
Mar 13, 2019 04:05PM Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Mar 12, 2019 10:00AM Ligand Provides Highlights from Today’s Analyst Day Event
Mar 6, 2019 07:30AM Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2018 on March 13, 2019
Feb 26, 2019 07:30AM Viking Therapeutics to Participate in Upcoming Investor Conferences and Events
Jan 2, 2019 07:30AM Viking Therapeutics to Present at Biotech Showcase 2019
Nov 13, 2018 05:53AM Viking Therapeutics (VKTX) Reports Results from Phase 2 Study of VK2809 in Patients with NAFLD & Elevated LDL-Cholesterol
Nov 12, 2018 06:55PM Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver
Nov 7, 2018 04:05PM Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Sep 18, 2018 07:08AM Viking Therapeutics (VKTX) Says Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol Achieved its Primary Endpoint
Sep 18, 2018 07:05AM Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
Aug 28, 2018 07:30AM Viking Therapeutics to Participate in Upcoming Investor Conferences
Aug 9, 2018 04:05PM Viking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Aug 2, 2018 07:30AM Viking Therapeutics to Report Financial Results for Second Quarter 2018 on August 9, 2018
Jun 5, 2018 07:06AM Viking Therapeutics (VKTX) Reports Complete Enrollment in Phase 2 Study of VK2809
Jun 5, 2018 07:01AM Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
May 9, 2018 04:05PM Viking Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 2, 2018 07:30AM Viking Therapeutics to Report Financial Results for First Quarter 2018 on May 9, 2018
Mar 7, 2018 04:05PM Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
Mar 6, 2018 07:00AM Viking Therapeutics to Present at Upcoming Investor Conferences
Feb 28, 2018 07:00AM Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018
Feb 7, 2018 07:05AM Viking Therapeutics to Present at 2018 BIO CEO & Investor Conference
Jan 2, 2018 07:05AM Viking Therapeutics to Present at Biotech Showcase 2018
Nov 28, 2017 07:05AM Viking Therapeutics (VKTX) Reports Positive Top-Line Results from Phase 2 Study of VK5211
Nov 28, 2017 07:02AM Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Nov 8, 2017 04:05PM Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Nov 1, 2017 07:30AM Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017
Oct 24, 2017 07:07AM Viking Therapeutics (VKTX) Announces Results from In Vivo Study of VK2809
Oct 24, 2017 07:05AM Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Dise
Oct 23, 2017 07:08AM Viking Therapeutics (VKTX) Announces Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
Oct 23, 2017 07:05AM Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association
Oct 4, 2017 07:06AM Viking Therapeutics (VKTX) Reports Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-ALD
Oct 4, 2017 07:05AM Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
Sep 25, 2017 07:30AM Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings
Sep 11, 2017 07:10AM Viking Therapeutics (VKTX) Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in NASH
Sep 11, 2017 07:05AM Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
Sep 7, 2017 07:13AM Viking Therapeutics (VKTX) Presents Data from In Vivo Proof-of-Concept Study of VK2809
Sep 7, 2017 07:02AM Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metaboli
Sep 5, 2017 07:30AM Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference
Aug 9, 2017 04:05PM Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Aug 2, 2017 07:30AM Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017
Jul 12, 2017 07:01AM Viking Therapeutics (VKTX) Completes Enrollment in Phase 2 Study of VK5211
Jul 12, 2017 07:00AM Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Jul 6, 2017 08:19AM Viking Therapeutics (VKTX) Names Charles Rowland Jr. to Board
Jul 6, 2017 08:00AM Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors
View More Recent Stories View Older Stories